ACE Inhibitor Reduces ESRD Risk Among Obese Patients - Renal and Urology News PDF Print
Renal and Urology News
Ramipril can essentially abolish the excess risk for end-stage renal disease (ESRD) seen in obese persons with chronic kidney disease (CKD), according to a post hoc analysis of the Ramipril Efficacy in Nephropathy (REIN) trial.

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.